Molecular Imaging in Noninvasive Assessment of Diabetes Progression

dc.contributor.advisorLenkinski, Roberten
dc.contributor.committeeMemberSun, Xiankaien
dc.contributor.committeeMemberÖz, Orhan K.en
dc.contributor.committeeMemberLingvay, Ildikoen
dc.contributor.committeeMemberAhn, Jung-Moen
dc.creatorLo, Su-Tangen
dc.date.accessioned2015-09-01T20:45:08Z
dc.date.available2015-09-01T20:45:08Z
dc.date.created2013-08
dc.date.issued2013-07-16
dc.date.submittedAugust 2013
dc.date.updated2015-09-01T19:56:59Z
dc.description.abstractMolecular imaging is a recently emerged multidisciplinary scientific field comprised of diverse technologies. The goal of this branch of science is to understand molecular mechanism of diseases and facilitate drug development, namely the interplay of non-invasive imaging techniques with molecular biology and medicine. The goal of this dissertation is to reflect the roles of molecular imaging in biomedical applications by longitudinal and non-invasive detection of the initiation and progression of diabetes. Diabetes is a chronic disease caused by a gradual loss of pancreatic β-cell mass (BCM). The current clinical diagnosis measures the parameters of the β-cell function (BCF) post the onset of the disease, which cannot accurately reflect the BCM loss during the initiation and progression of the disease. Therefore, a non-invasive imaging technique that enables the direct assessment of BCM change would be highly desirable. In this dissertation, Positron Emission Tomography (PET) imaging was conducted to non-invasively and longitudinally monitor the change of glucagon-like peptide 1 receptor (GLP-1R), a specific biomarker of pancreatic β-cell, during disease progression. Through a two-fold screening method, a modified bicyclic GLP-1 analog, which enhances biological stability while maintaining the receptor binding affinity, was selected. An imaging probe was therefore developed based on this selected stable GLP-1 analog for noninvasive imaging assessment of BCM. In vivo evaluation was carried out to determine the BCM targeting properties of the probe followed by ex vivo PET imaging and histology. Further, a reliable and reproducible multimodality imaging technique was developed by combining PET imaging with the GLP-1R targeted probe with anatomical imaging techniques including BaSO4-enhanced CT and MRI for quantitative analysis of BCM imaging in mouse models. To test the potential of the imaging technique for longitudinal monitoring of BCM change during the diabetes initiation and progression, a serial PET/CT imaging was performed in a streptozotocin (STZ)-induced diabetic mouse model. With the successful development of the BCM imaging probe, a valid imaging technique has been established for noninvasive assessment of the progression of diabetes, which may find applications in early diagnosis of diabetes and monitoring therapeutic interventions of the disease.en
dc.format.mimetypeapplication/pdfen
dc.identifier.oclc919526539
dc.identifier.urihttps://hdl.handle.net/2152.5/1740
dc.language.isoenen
dc.subjectDiabetes Mellitusen
dc.subjectDisease Progressionen
dc.subjectMolecular Imagingen
dc.subjectPositron-Emission Tomographyen
dc.titleMolecular Imaging in Noninvasive Assessment of Diabetes Progressionen
dc.typeThesisen
dc.type.materialTexten
thesis.date.available2015-09-01
thesis.degree.departmentGraduate School of Biomedical Sciencesen
thesis.degree.disciplineRadiological Sciencesen
thesis.degree.grantorUT Southwestern Medical Centeren
thesis.degree.levelDoctoralen
thesis.degree.nameDoctor of Philosophyen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
LO-DISSERTATION-2013.pdf
Size:
4.58 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 2 of 2
No Thumbnail Available
Name:
LICENSE.txt
Size:
1.84 KB
Format:
Plain Text
Description:
No Thumbnail Available
Name:
LICENSE_1.txt
Size:
1.84 KB
Format:
Plain Text
Description: